Botulinum Toxin Type A with Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients with Cerebral Palsy and Spastic Equinus Foot Deformity

Abstract

The objective of this study was to compare the effectiveness of baclofen versus tizanidine as adjuvant treatment of botulinum toxin type A botulinum toxin type A in the management of children with spasticity. Thirty children with gastrocnemius spasticity were retrospectively reviewed at Gaziantep University Hospital, Gaziantep, Turkey. All patients were treated with localized botulinum toxin injections and baclofen or tizanidine for spasticity and were followed at 2- to 4-week intervals and evaluated for a total of 12 weeks; 17 children (57%) received baclofen and 13 (43%) received tizanidine. The mean score of Gross Motor Functional Measurement (76.63 ± 5.88 vs 68.17 ± 1.99; P < .001) and caregiver questionnaire scores (70.23 ± 4.76 vs 66.59 ± 3.53; P = .03) for the tizanidine group were significantly higher as compared with the baclofen group. This study suggests that combination of botulinum toxin type A with oral tizanidine is more effective with fewer side effects than combination of botulinum toxin type A and oral baclofen for spastic cerebral palsy.

Keywords

cerebral palsy botulinum toxin tizanidine baclofen

Get full access to this article

View all access options for this article.

References

Kita M. , Goodkin DE Drugs used to treat spasticity. Drugs. 2000 ;59:487-495.

Goldstein M. , Harper DC Management of cerebral palsy: equinus gait . Dev Med Child Neurol. 2001;43:563-569.

Edgar TS Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol. 2001; 16:37-46.

Jefferson RJ Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol. 2004;46:491-499.

Tilton AH Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;3:58-65.

Al-Shahrani A. Anti-spasticity medications. Saudi Med J. 2003;24:19-22.

Koman LA , Smith BP , Shilt JS Cerebral palsy. Lancet. 2004; 363:1619-1631.

Graham HK , Aoki KR , Autti-Ramo I. , et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11:67-79.

Ljungman G. , Kreuger A. , Andreasson S. , et al. Midazolam nasal spray reduces procedural anxiety in children . Pediatrics. 2000; 105:73-78.

10.

Patel DR , Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72:869-872.

11.

Albright AL Baclofen in the treatment of cerebral palsy . J Child Neurol. 1996;11:77-83.

12.

Schneider JW , Gurucharri AL , Gaebler-Spira DJ Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol. 2001;43: 601-608.

13.

Russell DJ , Rosenbaum PL , Avery LM , Lane M. Gross Motor Function Measure (GMFM-66 and GMFM-88) User's Manual. London, England: Mac Keith Press; 2002:326-335.

14.

Hsieh JT , Wolfe DL , Miller WC , Curt A. ; the SCIRE Research Team. Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord . 2008;46: 86-95.

15.

Cardosa ES , Rodrigues BM , Barroso M. , et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neruol. 2006 ;34:106-109.